Research Article: Neonatal Derived Mesenchymal Stem Cell Mesotherapy in Androgenetic Alopecia: A Retrospective Observational Study and Review of Literature

This retrospective observational study evaluated the benefits and safety of mesotherapy using neonatal mesenchymal stem cells (MSC) in 40 patients with androgenetic alopecia (AGA) of grade 2 to 7. The results indicated that 70% of patients experienced a mild response, while 25% showed moderate improvement in hair growth and reduction in hair loss after four monthly treatments. One patient exhibited a 72% improvement. No major adverse events were reported, and patients were followed up for 6 months. The study concluded that while the findings were promising, larger randomized controlled studies with longer follow-ups were necessary to establish MSC therapy as a novel treatment option for AGA.